Alhanouf A. AlZahrani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alhanouf A. AlZahrani has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Al Sarkhy
Department of Pediatrics, Gastroenterology Unit, College of Medicine, King Saud University, Riyadh, Saudi Arabia
2 shared publications - Afnan A. AlSunaidi
Pharmacy Department, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
1 shared publication - Asaad Assiri
Gastroenterology Division, Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia
1 shared publication - Hayfa Alabdulkarim
Gastroenterology Division, Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia
1 shared publication - Mohammad El Mouzan
Department of Pediatrics (Gastroenterology Unit), College of Medicine, King Saud University, Riyadh, Saudi Arabia
1 shared publication - Mohammed Kambal
Gastroenterology Division, Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 26 November 2025
- Published by Wolters Kluwer Health in Saudi Journal of Gastroenterology
- Vol. 32 (1) , 22-32
Effectiveness and safety of upadacitinib in refractory pediatric inflammatory bowel disease: A single-arm meta-analysis of observational studies
Upadacitinib (UPA), a selective Janus kinase-1 (JAK-1) inhibitor, has been approved for adults with refractory inflammatory bowel disease (IBD). Its oral formulation and efficacy after biologic failures make it an attractive option for children with refractory IBD. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of UPA in children with moderate to severe IBD. We systematically searched PubMed, Embase, and the Cochrane Library until May 2025. Studies were included if they involved pediatric IBD patients (<18 years) treated with UPA and reported clinical or endoscopic outcomes. We excluded case reports/series with ≤5 patients, studies using multiple dual therapies, or those lacking predefined outcomes. Pooled rates were calculated using a random-effects model. Five retrospective studies, involving 248 patients (134 with ulcerative colitis (UC) and 114 with Crohn’s disease (CD), met the inclusion criteria. Post-induction, the pooled clinical response rate was 88% (95% CI: 76%–96%; I² = 58.9%), and the steroid-free clinical remission (SFCR) rate was 70% (95% CI: 54%–85%; I² = 69%). The rates for endoscopic response and remission were 82% (95% CI: 57%–98%; I² = 0%) and 36% (95% CI: 11%–64%; I² = 0%), respectively. During maintenance, SFCR rate was 76% (95% CI: 59%–89%; I² = 0%). Serious adverse events occurred at a rate of 9 per 100 person-years, with herpes zoster reactivation at 4 per 100 person-years. No venous thromboembolic events were reported. UPA may offer a therapeutic alternative for refractory pediatric IBD, but its efficacy and safety require prospective validation.
- 26 November 2025
- Published by Wolters Kluwer Health in Saudi Journal of Gastroenterology
- Vol. 32 (1) , 22-32
Open AccessEffectiveness and safety of upadacitinib in refractory pediatric inflammatory bowel disease: A single-arm meta-analysis of observational studies
Upadacitinib (UPA), a selective Janus kinase-1 (JAK-1) inhibitor, has been approved for adults with refractory inflammatory bowel disease (IBD). Its oral formulation and efficacy after biologic failures make it an attractive option for children with refractory IBD. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of UPA in children with moderate to severe IBD. We systematically searched PubMed, Embase, and the Cochrane Library until May 2025. Studies were included if they involved pediatric IBD patients (<18 years) treated with UPA and reported clinical or endoscopic outcomes. We excluded case reports/series with ≤5 patients, studies using multiple dual therapies, or those lacking predefined outcomes. Pooled rates were calculated using a random-effects model. Five retrospective studies, involving 248 patients (134 with ulcerative colitis (UC) and 114 with Crohn’s disease (CD), met the inclusion criteria. Post-induction, the pooled clinical response rate was 88% (95% CI: 76%–96%; I² = 58.9%), and the steroid-free clinical remission (SFCR) rate was 70% (95% CI: 54%–85%; I² = 69%). The rates for endoscopic response and remission were 82% (95% CI: 57%–98%; I² = 0%) and 36% (95% CI: 11%–64%; I² = 0%), respectively. During maintenance, SFCR rate was 76% (95% CI: 59%–89%; I² = 0%). Serious adverse events occurred at a rate of 9 per 100 person-years, with herpes zoster reactivation at 4 per 100 person-years. No venous thromboembolic events were reported. UPA may offer a therapeutic alternative for refractory pediatric IBD, but its efficacy and safety require prospective validation.
- Open Access
- 30 December 2024
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 66 (6) , 713-718
The outcome of functional constipation in Saudi children
Background. Understanding the outcome of functional constipation (FC) for both patients and physicians is essential, yet it has been infrequently reported worldwide. The objective of this report was to update the outcomes of FC in Saudi children. Methods. Clinical data including age, sex, response to management, duration of follow up, and type of management were collected from the notes of each clinic visits and phone call follow-ups. Results. The study included 268 children followed up for a 7 year duration. The median age of onset was 4 (0.1 to 13) years, and 123/268 (46%) were male. There was an increasing recovery rate with increasing duration of follow up with an overall recovery rate of 79%. There was no significant association between recovery and age at onset (p=0.0860) or duration of constipation (P=0.124). Management by pediatric gastroenterologists did not increase rate of recovery (81% vs. 77%, p=0.432) or being cured (47% vs. 36%, p=0.108) significantly. According to the parents of children who recovered, diet in association with polyethylene glycol (PEG) and toilet training were most helpful. Poor diet and nonadherence to medications were the most common causes of lack of recovery. Conclusions. The higher rates of recovery in this Middle Eastern childhood population than other populations are possibly related to cultural characteristics. The parents’ views support the importance of diet associated with other modalities as important parts of management. Further research is needed to identify correctable causes of nonadherence to treatment to improve recovery.
- 30 December 2024
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 66 (6) , 713-718
Open AccessThe outcome of functional constipation in Saudi children
Background. Understanding the outcome of functional constipation (FC) for both patients and physicians is essential, yet it has been infrequently reported worldwide. The objective of this report was to update the outcomes of FC in Saudi children. Methods. Clinical data including age, sex, response to management, duration of follow up, and type of management were collected from the notes of each clinic visits and phone call follow-ups. Results. The study included 268 children followed up for a 7 year duration. The median age of onset was 4 (0.1 to 13) years, and 123/268 (46%) were male. There was an increasing recovery rate with increasing duration of follow up with an overall recovery rate of 79%. There was no significant association between recovery and age at onset (p=0.0860) or duration of constipation (P=0.124). Management by pediatric gastroenterologists did not increase rate of recovery (81% vs. 77%, p=0.432) or being cured (47% vs. 36%, p=0.108) significantly. According to the parents of children who recovered, diet in association with polyethylene glycol (PEG) and toilet training were most helpful. Poor diet and nonadherence to medications were the most common causes of lack of recovery. Conclusions. The higher rates of recovery in this Middle Eastern childhood population than other populations are possibly related to cultural characteristics. The parents’ views support the importance of diet associated with other modalities as important parts of management. Further research is needed to identify correctable causes of nonadherence to treatment to improve recovery.